Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: Respirovirus) strain Moscow
Problems of Virology · 2023
DOI: 10.36233/0507-4088-172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Problems of Virology, 2023. Verfasst von G A Kudrov und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor. Hauptthemen laut MEDLINE: COVID-19, Viral Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Intranasal vaccination using live vector vaccines based on non-pathogenic or slightly pathogenic viruses is the one of the most convenient, safe and effective ways to prevent respiratory infections, including COVID-19. Sendai virus is the best suited for this purpose, since it is respiratory virus and is capable of limited replication in human bronchial epithelial cells without causing disease. The aim of the work is to design and study the vaccine properties of recombinant Sendai virus, Moscow strain, expressing secreted receptor-binding domain of SARS-CoV-2 Delta strain S protein (RBDdelta) during a single intranasal immunization. Materials and methods. Recombinant Sendai virus carrying insertion of RBDdelta transgene between P and M genes was constructed using reverse genetics and synthetic biology methods. Expression of RBDdelta was analyzed by Western blot. Vaccine properties were studied in two models: Syrian hamsters and BALB/c mice. Immunogenicity was evaluated by ELISA and virus-neutralization assays. Protectiveness was assessed by quantitation of SARS-CoV-2 RNA in RT-PCR and histological analysis of the lungs.
Results
Based on Sendai virus Moscow strain, a recombinant Sen-RBDdelta(M) was constructed that expressed a secreted RBDdelta immunologically identical to natural SARS-CoV-2 protein. A single intranasal administration of Sen-RBDdelta(M) to hamsters and mice significantly, by 15 and 107 times, respectively, reduced replicative activity of SARS-CoV-2 in lungs of animals, preventing the development of pneumonia. An effective induction of virus-neutralizing antibodies has also been demonstrated in mice.
Conclusion
Sen-RBDdelta(M) is a promising vaccine construct against SARS-CoV-2 infection and has a protective properties even after a single intranasal introduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor.
ORCID-Profile: G A Kudrov, S S Zainutdinov, A A Grazhdantseva, A V Shipovalov, G F Sivolobova, A V Semenova, I A Merkuleva, D N Shcherbakov, O S Taranov, A V Zaykovskaya, I S Shulgina, O V Pyankov, G V Kochneva
Zitieren
APA
Kudrov, G. A., Zainutdinov, S. S., Grazhdantseva, A. A., Shipovalov, A. V., Sivolobova, G. F., Semenova, A. V., Merkuleva, I. A., Shcherbakov, D. N., Taranov, O. S., Zaykovskaya, A. V., Shulgina, I. S., Pyankov, O. V., & Kochneva, G. V. (2023). Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: Respirovirus) strain Moscow. Problems of Virology. https://doi.org/10.36233/0507-4088-172
Vancouver
Kudrov GA, Zainutdinov SS, Grazhdantseva AA, Shipovalov AV, Sivolobova GF, Semenova AV, et al. Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: Respirovirus) strain Moscow. Problems of Virology. 2023. doi:10.36233/0507-4088-172
BibTeX
@article{Kudrov2023,
author = {Kudrov, G A and Zainutdinov, S S and Grazhdantseva, A A and Shipovalov, A V and Sivolobova, G F and Semenova, A V and Merkuleva, I A and Shcherbakov, D N and Taranov, O S and Zaykovskaya, A V and Shulgina, I S and Pyankov, O V and Kochneva, G V},
title = {Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: Respirovirus) strain Moscow},
journal = {Problems of Virology},
year = {2023},
doi = {10.36233/0507-4088-172}
}
EUVIMED